Clinical trials: Second-line Therapy
Osteosarcoma
Study of HS-20093 Versus Gemcitabine in Combination With Docetaxel in Treatment of Osteosarcoma After Previous Second-line Treatment Failure
This is a randomized, controlled, open, multicenter phase III clinical study to evaluate the efficacy and safety of HS-20093 for injection versus gemcitabine in combination with docetaxel in patients with osteosarcoma who have at…
- Trial name
- NCT06935409
- Testing
- HS-20093, Gemcitabine combined with docetaxel
- Where
- 2 sites in China
- Volunteers
- 122 people
- Sponsor
- Hansoh BioMedical R&D Company
Prostate Cancer
Observational Retrospective Trial on Sequential Hormonal Therapy in Patients With Prostate Cancer
Observational Retrospective trial on sequential hormonal therapy in patients with Prostate Cancer
- Trial name
- Sorse (NCT00668083)
- Where
- 12 sites in Italy
- Volunteers
- 214 people
- Sponsor
- AstraZeneca
Cancer, Relapsed Cancer
myCare-102: Clinical Utility and Usability of Cellworks Singula™ and Cellworks Ventura™ Reports
The purpose of this study is to determine the benefit of Cellworks Singula™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications who have already received…
- Conditions
- Cancer, Relapsed Cancer, Refractory Cancer
- Trial name
- myCare-102 (NCT05693831)
- Testing
- Cellworks Report
- Where
- United States
- Volunteers
- 730 people
- Sponsor
- Cellworks Group Inc.
Non-small Cell Lung Cancer Metastatic
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
In recent years, immunotherapy research has made great progress, especially the immunocheckpoint inhibitors represented by anti-pd-1 antibody have shown good efficacy in the treatment of malignant tumors, and some patients can…
- Trial name
- NCT04331626
- Testing
- Gemcitabine Injectable Product
- Volunteers
- 50 people
- Sponsor
- Henan Cancer Hospital
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
In this study researcher want to learn more about the overall survival in patients suffering from prostate gland cancer which spread outside the prostate to other parts of the body who received either a novel anti-hormone therapy…
- Trial name
- PHENIX (NCT03896984)
- Testing
- Radium-223 (Xofigo, BAY88-8223), Abiraterone, Enzalutamide
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Bayer
Second Line Treatment of Gastric Cancer
Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
This study is a multicenter, open, and randomized clinical phase II exploratory study. The "pick the winner" study design is used to determine and select which chemotherapy drug (irinotecan vs.
- Trial name
- NCT05669807
- Testing
- Camrelizumab, Albumin-Bound Paclitaxel, Irinotecan
- Volunteers
- 184 people
- Sponsor
- Zhejiang Cancer Hospital
Graft-vs-Host Disease
Research Study of Visilizumab for Treatment of Glucocorticoid- Refractory Graft Versus Host Disease
The purpose of this phase II study is to evaluate an investigational monoclonal antibody for the treatment of glucocorticoid-refractory Graft Versus Host Disease (GVHD).
- Trial name
- NCT00032279
- Testing
- Visilizumab
- Where
- 17 sites in United States
- Volunteers
- 80 people
- Sponsor
- Fred Hutchinson Cancer Center
Advanced Hepatocellular Carcinoma
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma
- Trial name
- NCT06301399
- Testing
- Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hodgkin Lymphoma
ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma
This is a single-arm, phase II, multi-centre study of the safety and efficacy of the PD-1 inhibitor, nivolumab, as second-line or third-line salvage therapy as a bridge to stem cell transplant (SCT) in relapsed/ refractory…
- Trial name
- ANIMATE (NCT03337919)
- Testing
- Nivolumab
- Where
- 10 sites in United Kingdom
- Volunteers
- 78 people
- Sponsor
- University College, London
Graft Vs Host Disease
Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease
Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.
- Trial name
- NCT00035880
- Testing
- ABX-CBL
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Abgenix
Esophageal Neoplasms
Anlotinib Retrospective Study for Esophageal Cancer
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and second line of advanced esophageal…
- Trial name
- NCT05303740
- Testing
- Anlotinib
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Feng Wang
Human Immunodeficiency Virus
Nucleosides And Darunavir/Dolutegravir In Africa
This trial evaluates options for second-line antiretroviral therapy in patients failing on a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF)-based first-line regimen in the setting of the public health…
- Trial name
- NADIA (NCT03988452)
- Testing
- Darunavir, Ritonavir, Dolutegravir
- Where
- Uganda
- Volunteers
- 465 people
- Sponsor
- Makerere University
Post-transplantation Lymphoproliferative Disorder
Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)
Post-transplantation lymphoproliferative disorder (PTLD) develops in one to ten per cent of transplant recipients and can be EBV-associated.
- Trial name
- NCT01458548
- Testing
- Rituximab, CHOP
- Where
- 4 sites in Australia, France and 2 more
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
HIV Infection, HIV Infections
Efficacy and Safety of Single Versus Double Ritonavir-boosted Protease Inhibitor (PI)-Based Antiretroviral Therapy (ART) Regimens
The virological efficacy will be no different in children treated with single versus double boosted PI second line ART regimens.
- Trial name
- NCT00886990
- Testing
- ritonavir-boosted PI-based second line treatments, two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
- Where
- 8 sites in Thailand
- Volunteers
- 240 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Metastatic Colorectal Cancer (CRC)
Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Colorectal Cancer
This study is a randomized, controlled, open-label, phase II clinical study. This study is designed to evaluate the efficacy and safety of second-line standard treatment sequential TAS-102 and bevacizumab combined with local…
- Trial name
- TASBEL (NCT06856187)
- Testing
- TAS-102+bevacizumab+local treatment, Standard chemotherapy
- Where
- China
- Volunteers
- 119 people
- Sponsor
- Fudan University
Lobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma
A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma
The purpose was to evaluate efficacy, safety and effects on survival for lobaplatin and Gemcitabine in combination with Docetaxel, which can provide a kind of completely new second-line chemotherapy program for osteosarcoma…
- Trial name
- NCT02099396
- Testing
- Docetaxel+lobaplatin, Gemcitabine+lobaplatin
- Volunteers
- 100 people
- Sponsor
- China Association of Osteosarcoma Chemotherapy
Non-Hodgkin's Lymphoma
Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL)
Oxaliplatin will be used instead of cisplatin in well-known salvage regimen of etoposide, methylprednisolone, cytarabine and cisplatin (ESHAP).
- Trial name
- NCT00336583
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 27 people
- Sponsor
- Asan Medical Center
Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
Patients with unresectable or metastatic gastric or esophageal cancer, with first-line treatment applied are to be recruited in the study.
- Trial name
- OASIS (NCT04503967)
- Testing
- Anlotinib Hydrochloride With Nivolumab
- Volunteers
- 48 people
- Sponsor
- Shanghai Zhongshan Hospital
ITP - Immune Thrombocytopenia
Immune Markers in Pediatric ITP on Second Line Therapy
Immune thrombocytopenia (ITP) is a common autoimmune disease characterized by low platelet count and increased risk of bleeding.
- Trial name
- NCT06093529
- Testing
- complete blood count, CD3+ , CD4+ , CD8+, CD16+, CD56+, IFN-γ.
- Volunteers
- 42 people
- Sponsor
- Assiut University
Lung Cancer (NSCLC)
Analysis of Different Second Line Treatment in Advanced NSCLC Patients Progressing After 1st Line Immune Checkpoint Inhibitor Therapy
The second-line treatment options in clinical practice for immunotherapy progress are complex. Treatment strategies need to be selected based on different progression patterns.
- Trial name
- NCT07596524
- Testing
- Observation
- Where
- 3 sites in China
- Volunteers
- 300 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences